Ortho Development has announced the full commercial launch of the Trivicta Hip Stem, a cementless femoral component designed for use in primary total hip arthroplasty. The launch follows a controlled market introduction and marks the system’s availability across the company’s full U.S. distribution network.

The system addresses a key clinical need in joint replacement surgery: achieving consistent implant stability and anatomical fit across diverse patient anatomies. Variability in femoral morphology and surgical approach can impact outcomes, making implant versatility and ease of placement critical factors in modern orthopedic practice.

Trivicta differentiates itself through its refined triple-taper design, engineered to support both initial and long-term stability. The implant incorporates a hydroxyapatite coating over sintered titanium beads to promote early osteointegration, clcwhile offering standard and extended offset options to enable lateralisation without affecting leg length. Additional features, including progressive neck lengths and optimised distal geometry, are intended to improve anatomical compatibility.

From an operational perspective, the system includes a hybrid broach design with integrated compaction features aimed at preserving bone while supporting accurate implant seating. Modular instrumentation and incremental sizing further contribute to procedural efficiency and consistency across surgical approaches.

The Trivicta system builds on prior regulatory clearance, positioning it as a commercially ready solution for orthopedic surgeons treating conditions such as osteoarthritis, fractures, and other degenerative hip disorders.

Target users include orthopedic surgeons and health systems performing primary hip replacement procedures, where demand continues to grow alongside aging populations and increasing incidence of joint degeneration.